Top Publications from FY17 Based on Impact Factor

  1. Dombi E; Baldwin A; Marcus LJ; Fisher MJ; Weiss B; Kim A; Whitcomb P; Martin S; Aschbacher-Smith LE; Rizvi TA. Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas. The New England journal of medicine. 2016; 375:2550-2560.
  2. Rotz SJ; Dandoy CE; Davies SM. ST2 and Endothelial Injury as a Link between GVHD and Microangiopathy. The New England journal of medicine. 2017; 376:1189-1190.
  3. Fang J; Liu X; Bolanos L; Barker B; Rigolino C; Cortelezzi A; Oliva EN; Cuzzola M; Grimes HL; Fontanillo C. A calcium- and calpain-dependent pathway determines the response to lenalidomide in myelodysplastic syndromes. Nature Medicine. 2016; 22:727-734.
  4. Kesarwani M; Kincaid Z; Gomaa A; Huber E; Rohrabaugh S; Siddiqui Z; Bouso MF; Latif T; Xu M; Komurov K. Targeting c-FOS and DUSP1 abrogates intrinsic resistance to tyrosine-kinase inhibitor therapy in BCR-ABL-induced leukemia. Nature Medicine. 2017; 23:472-482.
  5. Cabezas-Wallscheid N; Buettner F; Sommerkamp P; Klimmeck D; Ladel L; Thalheimer FB; Pastor-Flores D; Roma LP; Renders S; Zeisberger P. Vitamin A-Retinoic Acid Signaling Regulates Hematopoietic Stem Cell Dormancy. Cell. 2017; 169:807-823.e19.
  6. Cavalli FMG; Remke M; Rampasek L; Peacock J; Shih DJH; Luu B; Garzia L; Torchia J; Nor C; Morrissy AS. Intertumoral Heterogeneity within Medulloblastoma Subgroups. Cancer Cell. 2017; 31:737-754.e6.
  7. Lin S; Luo RT; Ptasinska A; Kerry J; Assi SA; Wunderlich M; Imamura T; Kaberlein JJ; Rayes A; Althoff MJ. Instructive Role of MLL-Fusion Proteins Revealed by a Model of t(4;11) Pro-B Acute Lymphoblastic Leukemia. Cancer Cell. 2016; 30:737-749.
  8. Torchia J; Golbourn B; Feng S; Ho KC; Sin-Chan P; Vasiljevic A; Norman JD; Guilhamon P; Garzia L; Agamez NR. Integrated (epi)-Genomic Analyses Identify Subgroup-Specific Therapeutic Targets in CNS Rhabdoid Tumors. Cancer Cell. 2016; 30:891-908.
  9. Niederkorn M; Starczynowski DT. GMP-ing to Spatial Conclusions about Emergency and Leukemic Myelopoiesis. Cell Stem Cell. 2017; 20:579-581.
  10. Ramaswamy V; Hielscher T; Mack SC; Lassaletta A; Lin T; Pajtler KW; Jones DTW; Luu B; Cavalli FMG; Aldape K. Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort Analysis. Journal of Clinical Oncology. 2016; 34:2468-2477.
  11. von Stackelberg A; Locatelli F; Zugmaier G; Handgretinger R; Trippett TM; Rizzari C; Bader P; O'Brien MM; Brethon B; Bhojwani D. Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia. Journal of Clinical Oncology. 2016; 34:4381-4389.
  12. Fang J; Bolanos LC; Choi K; Liu X; Christie S; Akunuru S; Kumar R; Wang D; Chen X; Greis KD. Ubiquitination of hnRNPA1 by TRAF6 links chronic innate immune signaling with myelodysplasia. Nature Immunology. 2017; 18:236-245.
  13. Wu LMN; Wang J; Conidi A; Zhao C; Wang H; Ford Z; Zhang L; Zweier C; Ayee BG; Maurel P. Zeb2 recruits HDAC-NuRD to inhibit Notch and controls Schwann cell differentiation and remyelination. Nature Neuroscience. 2016; 19:1060-1072.
  14. He D; Wang J; Lu Y; Deng Y; Zhao C; Xu L; Chen Y; Hu YC; Zhou W; Lu QR. lncRNA Functional Networks in Oligodendrocytes Reveal Stage-Specific Myelination Control by an lncOL1/Suz12 Complex in the CNS. Neuron. 2017; 93:362-378.
  15. Chandrakasan S; Marsh RA; Uzel G; Holland SM; Shah KN; Bleesing J. Outcome of patients with NEMO deficiency following allogeneic hematopoietic cell transplant. Journal of Allergy and Clinical Immunology. 2017; 139:1040-1043.e2.
  16. de la Morena MT; Leonard D; Torgerson TR; Cabral-Marques O; Slatter M; Aghamohammadi A; Chandra S; Murguia-Favela L; Bonilla FA; Kanariou M. Long-term outcomes of 176 patients with X-linked hyper-IgM syndrome treated with or without hematopoietic cell transplantation. Journal of Allergy and Clinical Immunology. 2017; 139:1282-1292.
  17. Du W; Amarachintha S; Wilson A; Pang Q. The immune receptor Trem1 cooperates with diminished DNA damage response to induce preleukemic stem cell expansion. Leukemia. 2017; 31:423-433.
  18. Itkin T; Kumari A; Schneider E; Gur-Cohen S; Ludwig C; Brooks R; Kollet O; Golan K; Khatib-Massalha E; Russo CM. MicroRNA-155 promotes G-CSF-induced mobilization of murine hematopoietic stem and progenitor cells via propagation of CXCL12 signaling. Leukemia. 2017; 31:1247-1250.
  19. Varney ME; Choi K; Bolanos L; Christie S; Fang J; Grimes LH; Maciejewski JP; Inoue JI; Starczynowski DT. Epistasis between TIFAB and miR-146a: neighboring genes in del(5q) myelodysplastic syndrome. Leukemia. 2017; 31:491-495.
  20. Byrnes JR; Wilson C; Boutelle AM; Brandner CB; Flick MJ; Philippou H; Wolberg AS. The interaction between fibrinogen and zymogen FXIII-A(2)B(2) is mediated by fibrinogen residues gamma 390-396 and the FXIII-B subunits. Blood. 2016; 128:1969-1978.
  21. Chandrakasan S; Jayavaradhan R; Ernst J; Shrestha A; Loberg A; Dexheimer P; Jordan M; Pang Q; Aronow B; Malik P. KIT blockade is sufficient for donor hematopoietic stem cell engraftment in Fanconi anemia mice. Blood. 2017; 129:1048-1052.
  22. Holtan SG; Khera N; Levine JE; Chai X; Storer B; Liu HD; Inamoto Y; Chen GL; Mayer S; Arora M. Late acute graft-versus-host disease: a prospective analysis of clinical outcomes and circulating angiogenic factors. Blood. 2016; 128:2350-2358.
  23. Lounder DT; Khandelwal P; Dandoy CE; Jodele S; Grimley MS; Wallace G; Lane A; Taggart C; Teusink-Cross AC; Lake KE. Lower levels of vitamin A are associated with increased gastrointestinal graft-versus-host disease in children. Blood. 2017; 129:2801-2807.
  24. McGann PT; Hernandez AG; Ware RE. Sickle cell anemia in sub-Saharan Africa: advancing the clinical paradigm through partnerships and research. Blood. 2017; 129:155-161.
  25. Mehta PA; Davies SM; Leemhuis T; Myers K; Kernan NA; Prockop SE; Scaradavou A; O'Reilly RJ; Williams DA; Lehmann L. Radiation-free, alternative-donor HCT for Fanconi anemia patients: results from a prospective multi-institutional study. Blood. 2017; 129:2308-2315.
  26. Rubin TS; Zhang K; Gifford C; Lane A; Choo S; Bleesing JJ; Marsh RA. Perforin and CD107a testing is superior to NK cell function testing for screening patients for genetic HLH. Blood. 2017; 129:2993-2999.
  27. Shaw MA; Kombrinck KW; McElhinney KE; Sweet DR; Flick MJ; Palumbo JS; Cheng M; Esmon NL; Esmon CT; Brill A. Limiting prothrombin activation to meizothrombin is compatible with survival but significantly alters hemostasis in mice. Blood. 2016; 128:721-731.